

Takehiro Tozuka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4203239/publications.pdf>

Version: 2024-02-01

15
papers

169
citations

1163117

8
h-index

1199594

12
g-index

18
all docs

18
docs citations

18
times ranked

259
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. <i>BMC Cancer</i> , 2020, 20, 207. | 2.6 | 26 |
| 2 | Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 6851-6857. | 1.1 | 24 |
| 3 | Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy094. | 0.4 | 23 |
| 4 | Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. <i>Lung Cancer</i> , 2020, 144, 71-75. | 2.0 | 21 |
| 5 | Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice. <i>Thoracic Cancer</i> , 2021, 12, 504-511. | 1.9 | 18 |
| 6 | Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients. <i>Anticancer Research</i> , 2021, 41, 2093-2100. | 1.1 | 12 |
| 7 | Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer. <i>In Vivo</i> , 2020, 34, 2997-3003. | 1.3 | 11 |
| 8 | A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5879-5883. | 2.0 | 10 |
| 9 | Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5601-5605. | 2.0 | 7 |
| 10 | Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases. <i>Thoracic Cancer</i> , 2020, 11, 2465-2472. | 1.9 | 7 |
| 11 | Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib. <i>Cancer Reports</i> , 2021, , e1414. | 1.4 | 4 |
| 12 | Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2. <i>Thoracic Cancer</i> , 2021, 12, 906-913. | 1.9 | 3 |
| 13 | Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report. <i>OncoTargets and Therapy</i> , 0, Volume 15, 637-642. | 2.0 | 2 |
| 14 | Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100249. | 1.7 | 1 |
| 15 | Efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases. <i>Journal of Clinical Oncology</i> , 2020, 38, e14511-e14511. | 1.6 | 0 |